Skip to content

Novavax NVAX Investment Proceeds

Investment Proceeds at other companies

Moderna logo
ModernaMRNA
$602M-12.5%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$24.88M-4.5%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$168.6M-1.6%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$101.48M+46.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$79.38M+1,384%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$221.24M+191%

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's investment proceeds?
Novavax (NVAX) reported investment proceeds of $147.29M in Q1 2026.
How has Novavax's investment proceeds changed year-over-year?
Novavax's investment proceeds increased by 242.5% year-over-year, from $43M to $147.29M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.